Hormonal health is now widely described as one of the fastest-growing verticals in femtech – in Europe, arguably the fastest-growing one.The clearest expression of that momentum is the race toward continuous hormone monitoring, which we’ve covered in depth on Femtech Insider: Level Zero Health raised $6.9 million for its DNA-based biosensors, and in June, Clair Health raised an $11.6 million seed round led by Khosla Ventures to build a noninvasive wearable hormone monitor – a round that says as much about investor appetite as it does about technology. Around them, an entire measurement ecosystem is filling in: Saliva-based testing (Eli Health, Inne), urine-based platforms (Mira, Oova, Proov, Hormona), at-home blood testing (Hertility), and just in the past few weeks, Kāhu SiliconBio’s £1.2 million for continuous monitoring and Kompass Diagnostics scaling rapid finger-prick hormone testing.
The infrastructure layer is moving too. SPRIND’s €40 million Hormone Challenge – which we covered earlier this year – is funding the shared reference dataset the whole field depends on. And on the care side, menopause is now the fastest-heating sub-sector in women’s health per Dealroom, while therapeutics are getting in on it as well (see Estrigenix’s raise for selective estrogen therapy just a few weeks ago).
So yes: Hormonal health is a rising category. But here’s the thing I keep coming back to. When a cervical dilation probe, a perimenopause focus-forecasting app, and an iron-fortified coffee can all sit adjacent to the same buzzword, the category label has stopped explaining anything and it’s time to unpack it, so we can all get on the same page as to what we actually mean when we talk about hormonal health.
When we map the hormonal health landscape at Femtech Insider, we break it down into four segments – and the reason this framework has held up is that each segment describes a different problem, which in turn maps to a different corner of the innovation landscape. Different customer, different business model, different evidence bar, different regulatory path
1. Hormone Health Across the Lifespan → Innovation in Reproductive Health
The first segment is hormonal change as a feature, not a bug: The major transitions every woman moves through – puberty and menarche, fertility and pregnancy, the menopausal transition. Nothing here is a disorder. These are predictable, physiological shifts, and the innovation opportunity is supporting people through them
This is where most of what we’d traditionally call reproductive health innovation lives: fertility diagnostics and care platforms, pregnancy and postpartum support, and the entire menopause wave – from Midi Health’s insurance-covered care model to the life-stage platforms (Maven, Sword’s Bloom, Kindbody) that increasingly bundle these transitions into one offering. When investors say “hormonal health is hot,” a lot of the capital they’re pointing at is actually here – in lifespan transitions, menopause above all.
2. Hormone Health & the Cycle → Innovation in Menstrual Health
The second segment zooms in from years to weeks: The fluctuations within the menstrual cycle itself. Again, not a disorder – a rhythm. The problem being solved here is fundamentally an information problem: Most women were never taught what their hormones do across a cycle, and until recently there was no consumer-grade way to observe it
This is the home turf of menstrual health innovation: cycle tracking, fertility awareness, and the newer generation of cycle-informed products – training plans, nutrition, energy and mood forecasting. It’s also where the continuous monitoring race will land first commercially, because a real-time hormone signal turns cycle tracking from retrospective pattern-matching into something closer to a live dashboard.
3. Hormone Imbalance from External Factors → Education, Wellness & “Clean Products”
The third segment is where hormones go off-script because of something outside the body: endocrine-disrupting chemicals, environmental exposures, chronic stress, lifestyle. Readers of our December issue on the environmental blind spot in women’s health know I take the underlying science seriously – microplastics, air pollution, and EDCs are showing up in the research with increasing regularity, including in the fertility data presented at ESHRE this summer.
But notice which corner of the market this maps to: Not clinical care, but education and consumer wellness – “clean” personal care products, hormone-safe swaps, supplements, detox-adjacent offerings. And that’s precisely why this is the segment I’d watch with the most nuance. It contains both the most legitimate unmet need for translation of emerging science and the most marketing that runs ahead of the evidence. “Hormone-balancing” remains one of the least-regulated claims in wellness. The long-term winners here, I suspect, will be the ones who treat the science as the product rather than the aesthetic.
4. Hormone Imbalance from Internal Factors → Primary & Chronic Care, Endocrinology
The fourth segment is clinical: hormone imbalance driven by illness or chronic condition – PCOS, thyroid disorders, endometriosis-adjacent hormonal dysfunction, premature ovarian insufficiency, and the long tail of endocrine conditions. This is disease, and it maps to primary care, chronic care management, and endocrinology
It’s also, I’d argue, the segment where the mismatch between burden and innovation is largest. PCOS affects roughly 1 in 10 women of reproductive age – the most common hormonal disorder in that population – and as I wrote in our State of PCOS Innovation deep dive, the innovation pipeline still doesn’t remotely match the prevalence. New research keeps raising the stakes: just last week, a study linked PCOS to increased cardiovascular disease risk. Meanwhile access to endocrinology remains one of medicine’s tightest bottlenecks. When capital flows into “hormonal health,” proportionally little of it lands here – and this is the segment where clinical outcomes, and arguably defensible businesses, are most clearly available.
Here’s why I keep insisting on the distinction
If you’re a founder, the segment you’re in determines who pays you. Segment one increasingly sells to payers and employers. Segment two sells to consumers. Segment three sells to consumers too – but on trust and brand, with a wellness margin structure and a reputational exposure the others don’t carry. Segment four sells into the healthcare system, with the evidence requirements and sales cycles that implies.”We’re a hormonal health company” tells me almost nothing; which of these four problems you’re solving tells me most of what I need to know.
If you’re an investor, the aggregate category numbers blend four very different risk profiles into one line item. A “hormonal health is booming” thesis built on menopause care momentum doesn’t automatically transfer to a supplement brand or a PCOS program – and vice versa
And one layer genuinely cuts across all four: Measurement. Continuous and at-home hormone testing is the shared infrastructure play – the same underlying data serves lifespan transitions, cycle intelligence, exposure questions, and chronic condition management. That’s the strongest argument for why the monitoring race is attracting the capital it is: whoever owns the hormone data layer touches every segment. Whether any of the current contenders can move from validation to commercialization at clinical grade is, as we said in the half-year recap, one of the open questions of H2.
The category is real, and it’s rising. But the next phase of its growth will be built by people who are precise about which hormonal health problem they’re actually solving.The word “hormonal” is where the conversation starts – it shouldn’t be where it ends
